HOME - News - Detail
First oral antiviral for COVID-19, Lagevrio (molnupiravir)
First oral antiviral for COVID-19, Lagevrio (molnupiravir)

The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.


The UK regulator, the MHRA, said the tablet had been authorised for use in people who have mild to moderate Covid and at least one risk factor for developing severe illness such as obesity, old age, diabetes or heart disease.

The new treatment targets an enzyme that the virus uses to make copies of itself, introducing errors into its genetic code. That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.

Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid which can be taken as a pill rather than injected or given intravenously.

Merck plans to produce the required quantity for 10 million courses of medicine by the end of 2021.


back to news